375 related articles for article (PubMed ID: 20521223)
1. Cancer therapy with bispecific antibodies: Clinical experience.
Thakur A; Lum LG
Curr Opin Mol Ther; 2010 Jun; 12(3):340-9. PubMed ID: 20521223
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibody Armed T Cells to Target Cancer Cells.
Thakur A; Lum LG; Mittal S
Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
4. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
5. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
6. [Bispecific Antibodies: Formats and Areas of Application].
Vasilenko EA; Mokhonov VV; Gorshkova EN; Astrakhantseva IV
Mol Biol (Mosk); 2018; 52(3):380-393. PubMed ID: 29989572
[TBL] [Abstract][Full Text] [Related]
7. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
8. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
10. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
11. Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
Fitzgerald J; Lugovskoy A
MAbs; 2011; 3(3):299-309. PubMed ID: 21393992
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
13. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
14. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
15. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
17. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.
Byrne H; Conroy PJ; Whisstock JC; O'Kennedy RJ
Trends Biotechnol; 2013 Nov; 31(11):621-32. PubMed ID: 24094861
[TBL] [Abstract][Full Text] [Related]
18. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
19. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
20. Bispecific and multispecific antibodies in oncology: opportunities and challenges.
Goebeler ME; Stuhler G; Bargou R
Nat Rev Clin Oncol; 2024 Jul; 21(7):539-560. PubMed ID: 38822215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
